Drug intelligence / Profile preview

amitriptyline + desipramine + imipramine

Development stage
Unknown
Lead developer
Merck
Modality
Small Molecules
Administration
Oral, Intramuscular
01

Overview

This is a combination of three tricyclic antidepressants (TCAs): amitriptyline, desipramine, and imipramine. All three are small molecule drugs that act primarily by inhibiting the reuptake of serotonin and norepinephrine in the central nervous system, thereby increasing their synaptic concentrations. This mechanism enhances mood and can relieve symptoms of depression. Each component has additional pharmacological effects due to interactions with other neurotransmitter systems (e.g., histaminergic, cholinergic), contributing to both therapeutic effects and side effect profiles. While each drug is individually approved for depression and other indications such as neuropathic pain or enuresis (imipramine), there is no widely recognized fixed-dose combination product containing all three agents together; this entry describes a hypothetical or compounded mixture.

02

Targets

SERT (Sodium-dependent serotonin transporter)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)ADRA1A (α1A)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on amitriptyline + desipramine + imipramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amitriptyline + desipramine + imipramine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call